Sector News

Stryker CEO says he remains focused on acquisitions

January 29, 2015
Life sciences
(Reuters) – The chief executive officer of U.S. medical device maker Stryker Corp (SYK.N), recently rumored to have been preparing a bid for British rival Smith & Nephew Plc (SN.L), said on Tuesday that acquisitions are his top priority for spending cash, but he gave no hint that any sort of deal was imminent.
The timing of acquisitions is unpredictable, Stryker Chief Executive Officer Kevin Lobo said on the company’s fourth-quarter earnings conference call.
“Right now we are pursuing the acquisition deal flow, and we’ll see what happens,” Lobo said. “We do plan to put our money to work.”Rumors that Stryker could bid soon for fellow orthopedic implant maker Smith & Nephew, frequently named as a possible takeover candidate, surfaced late last month.
Smith & Nephew CEO Olivier Bohuon, speaking earlier this month at an investor conference, said the company had not decided to follow other medical device makers that are bulking up through mergers.
Years of slow growth and persistent price erosion have prompted some large mergers in the orthopedic implant sector, with Johnson & Johnson (JNJ.N) buying Swiss device maker Synthes for about $21 billion in 2012, and Zimmer Holdings Inc (ZMH.N) in the process of acquiring privately held Biomet for $13.4 billion.
Stryker itself has been active in acquiring smaller companies, including its $1.65 billion deal for Mako Surgical Corp in 2013.
The Kalamazoo, Michigan-based maker of artificial hips and knees and other hospital supplies said on Tuesday its fourth-quarter net earnings fell 33 percent to $260 million, or 67 cents a share, hurt by charges for product recalls and costs related to opening a regional headquarters in Europe.
The company earned $386 million, or $1.01 a share, a year ago. Sales rose 6.1 percent to $2.62 billion in the latest quarter.
(Reporting by Susan Kelly in Chicago. Editing by Andre Grenon)

1 response to “Stryker CEO says he remains focused on acquisitions

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend